Department of Defense Awards Emergent BioSolutions With $235.8 Million Contract for Anthrax Vaccine
The BioThrax vaccine is indicated for active immunization to prevent anthrax disease caused by Bacillus anthracis in individuals aged 18 through 65 years.
